Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

Wealthy Chinese consumers are likely to spend three times more than their peers on post-retirement healthcare over the next ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through education and athlete stories.

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

Specialty Medicines delivered 15% growth to £3.3 billion, led by Respiratory, Immunology & Inflammation up 10%, Oncology up 42%, and HIV up 12%. CEO Emma Walmsley said the performance reflects “strong ...

The UK drugmaker’s best-selling shingles shot Shingrix as well as specialty medicines including drugs for asthma, HIV and cancer underpinned the brighter outlook ...

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...